Biomedicine

Drug Development Of A Novel “first-in-class” Itch E3 Ubiquitin Ligase Inhibitor Against Human Cancers

Principle Investigator:Yun Yen(TMU)
Abstract

1learn more
Team Introduction
Goals and Plan
Entry Barrier
Market Scope